[email protected]   +1 (304) 306-0723

High grade intraepithelial lesion (HSIL) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2030

$6,500.00$19,500.00

Clear

Description

High-grade squamous intraepithelial lesion (HSIL) corresponds moderately to severely abnormal squamous cells and represents 0.5% of all cervical smears. When an infection with high-risk HPV persists, it may lead to precancerous lesions either low grade squamous intraepithelial lesions (LSIL) for type 1 cervical intraepithelial neoplasia (CIN 1) or high grade squamous intraepithelial lesions (HSIL) for CIN 2 and 3. These precancerous lesions may progress to a cervical cancer within 10 to 20 years of evolution.

High-grade squamous intraepithelial lesion (HSIL) Epidemiology

Human papillomavirus types 16 and 18 are associated with approximately 25% of low-grade and 50% of high-grade cervical intraepithelial lesions worldwide. In the United States, HPV vaccination coverage has increased since vaccine introduction, and varies by age which has led to the decline in cases of HSIL in 15 to 24 years age-group, but no decreases have been seen in the age group from 25-39 years. The estimated numbers of U.S. CIN2+ cases were 196,000 (2016), with an estimated 76% attributable to 9-valent HPV vaccine types. In 2020, the estimated cases in US are XX million, European 5 countries (Germany, France, Italy, Spain & UK) are XX million and Japan has estimated cases of XX million. In G7, the number with High-Grade Cervical Dysplasia (HSIL) is projected to increase to XX billion in 2030.
HSIL Epidemiology HIGH Grade Cervical Dysplasia

High-grade squamous intraepithelial lesion (HSIL) Market Forecast

Market Size of High-Grade Cervical Dysplasia (HSIL) in the G7 is estimated to be XX million in 2020 and is expected to reach XX million by 2030. The market includes a surgical treatment options for High-Grade Cervical Dysplasia (HSIL) treatment.
There is a high unmet need for a new, safe non-invasive treatment especially for HSIL, to resolve cervical dysplasia and become HPV free. Any treatment that would avoid the side effects associated with procedures like LEEP would be significant patient benefit and healthcare cost savings. Several clinical trials testing immune therapies for HPV disease are currently open.The goal is to develop a combinatorial HPV immunotherapy approach that could be applied to all women with established HPV infections, that would ultimately eliminate the need for the complex and expensive screening, long-term follow-up, and surgical interventions currently employed to manage HPV disease. The identification of specific HPV antigens makes this disease an ideal model to develop antigen-specific immunotherapies for other chronic viral diseases, such as hepatitis, and ultimately, non-virus-associated cancers.
High grade intraepithelial lesion (HSIL) Market Forecast

Report Highlights

  • HSIL Current Market Trends
  • HSIL Current & Forecasted Cases across the G7 Countries
  • HSIL Market Opportunities And Sales Potential for Agents
  • HSIL Patient-based Market Forecast to 2030
  • HSIL Untapped Business Opportunities
  • HSIL Product Positioning Vis-a-vis Competitors’ Products
  • HSIL KOLs Insight

Additional information

Price

2-3 User License, Enterprise License, Single User License, Site User License

Table of Contents

  • High-Grade Cervical Dysplasia (HSIL) Disease Background
    • High-Grade Cervical Dysplasia (HSIL) Definition
    • Symptoms
    • Risk Factor
    • Diagnosis
  • Epidemiology Estimated and Forecast to 2030
    • Epidemiology Research Method & Data Sources Used
      • Prevalent Cases of High-Grade Cervical Dysplasia (HSIL) in the United States 2020-2030
      • Treated Cases of of High-Grade Cervical Dysplasia (HSIL) in the United States 2020-2030
      • Prevalent Cases of High-Grade Cervical Dysplasia (HSIL) in Germany 2020-2030
      • Treated Cases of of High-Grade Cervical Dysplasia (HSIL) in Germany 2020-2030
      • Prevalent Cases of High-Grade Cervical Dysplasia (HSIL) in France 2020-2030
      • Treated Cases of of High-Grade Cervical Dysplasia (HSIL) in France 2020-2030
      • Prevalent Cases of High-Grade Cervical Dysplasia (HSIL) in Italy 2020-2030
      • Treated Cases of of High-Grade Cervical Dysplasia (HSIL) in Italy 2020-2030
      • Prevalent Cases of High-Grade Cervical Dysplasia (HSIL) in Spain 2020-2030
      • Treated Cases of of High-Grade Cervical Dysplasia (HSIL) in Spain 2020-2030
      • Prevalent Cases of High-Grade Cervical Dysplasia (HSIL) in the United Kingdom 2020-2030
      • Treated Cases of of High-Grade Cervical Dysplasia (HSIL) in the United Kingdom 2020-2030
      • Prevalent Cases of High-Grade Cervical Dysplasia (HSIL) in Japan 2020-2030
      • Treated Cases of of High-Grade Cervical Dysplasia (HSIL) in Japan 2020-2030
  • Current Unmet Needs in High-Grade Cervical Dysplasia (HSIL)
  • Current Treatment Paradigm
    • Treatment/Prevention guidelines for High-Grade Cervical Dysplasia (HSIL)
    • Regulatory Approvals/Indication and Current Benchmarks
  • Emerging Therapies Chapters
    • Cevira (Asieris)
    • VGX-3100/CELLECTRA (Inovio)
    • INTERFERON ALPHA-2B (Better Life Pharma)
  • Emerging Vaccine Chapters
    • Gardasil (Merck)
    • HPV-16/18 vaccine (Shanghai Zerun Biotechnology Co.,Ltd)
    • BLS-ILB-E710c (BioLeaders Corporation)
    • GX-188E (Genexine, Inc.)
    • Others
  • KOLs Insight (US, EU, JP)
    • Unmet Needs
    • Analysis of the progresses in terms of approvals & current pipeline;
    • Impact on the treatment algorithm and product positioning
    • Relevance of new targets/platforms/ Therapy Uptake Share %
    • Physicians Preferences for the new pharmacological agents
  • What’s New in 2020
  • Future Treatment Paradigm
    • High-Grade Cervical Dysplasia (HSIL) Competitor Landscape and Approvals Anticipated
    • Future Treatment Algorithms and Competitor Positioning
    • Key Data Summary for Emerging Treatment
  • Late Phase Therapies Strategic Considerations in High-Grade Cervical Dysplasia (HSIL)
  • Total Market Forecast
    • Key Summary Findings
      • G7 total Market for High-Grade Cervical Dysplasia (HSIL) 2020-2030 (USD Million)
      • G7 total Market for High-Grade Cervical Dysplasia (HSIL) by Therapies 2020-2030 (USD Million)
    • Market Forecast by Country
      • United States
        • United States Market for High-Grade Cervical Dysplasia (HSIL) 2020-2030 (USD Million)
        • United States Market for High-Grade Cervical Dysplasia (HSIL) by Therapies 2020-2030 (USD Million)
      • Germany
        • Germany Market for High-Grade Cervical Dysplasia (HSIL) 2020-2030 (USD Million)
        • Germany Market for High-Grade Cervical Dysplasia (HSIL) by Therapies 2020-2030 (USD Million)
      • France
        • France Market for High-Grade Cervical Dysplasia (HSIL) 2020-2030 (USD Million)
        • France Market for High-Grade Cervical Dysplasia (HSIL) by Therapies 2020-2030 (USD Million)
      • Italy
        • Italy Market for High-Grade Cervical Dysplasia (HSIL) 2020-2030 (USD Million)
        • Italy Market for High-Grade Cervical Dysplasia (HSIL) by Therapies 2020-2030 (USD Million)
      • Spain
        • Spain Market for High-Grade Cervical Dysplasia (HSIL) 2020-2030 (USD Million)
        • Spain Market for High-Grade Cervical Dysplasia (HSIL) by Therapies 2020-2030 (USD Million)
      • United Kingdom
        • United Kingdom Market for High-Grade Cervical Dysplasia (HSIL) 2020-2030 (USD Million)
        • United Kingdom Market for High-Grade Cervical Dysplasia (HSIL) by Therapies 2020-2030 (USD Million)
      • Japan
        • Japan Market for High-Grade Cervical Dysplasia (HSIL) 2020-2030 (USD Million)
        • Japan Market for High-Grade Cervical Dysplasia (HSIL) by Therapies 2020-2030 (USD Million)
      • Market Drivers & Barriers
Name
Email
Phone
Enquiry

You may also like…

Get In Touch

Let's keep the conversation going